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Summary Potassium 2-{[(2Z)-(3-hydroxy-1-methyl-2-
butenylidene)]amino}-4-methyl-pentanoate (L1HK) and
potassium 2-{[(E)-1-(2-hydroxyphenyl)alkylidene]amino}-
4-methyl-pentanoates (L2HK-L3HK) underwent reactions
with PhnSnCl4-n (n=2 and 3) to give the amino acetate
functionalized Schiff base organotin(IV) complexes
[Ph3SnLH]n (1–3) and [Ph2SnL] (4), respectively. These
complexes have been characterized by 1H, 13C, 119Sn
NMR, IR spectroscopic techniques in combination with
elemental analyses. The crystal structures of 1 and 3 were
determined. The crystal structures reveal that the complexes
exist as polymeric chains in which the L-bridged Sn-atoms
adopt a trans-R3SnO2 trigonal bipyramidal configuration
with the Ph groups in the equatorial positions and the axial
locations occupied by a carboxylate oxygen atom from one
carboxylate ligand and the alcoholic or phenolic oxygen
atom of the next carboxylate ligand in the chain. The
carboxylate ligands coordinate in the zwitterionic form with
the alcoholic/phenolic proton moved to the nearby nitrogen
atom. The solution structures were predicted by 119Sn NMR
spectroscopy. When these organotin(IV) complexes were
tested against A498, EVSA-T, H226, IGROV, M19 MEL,
MCF7 and WIDR human tumor cell lines, the average ID50
values obtained were 55, 80 and 35 ng/ml for triphenyltin
(IV) compounds 1–3, respectively. The most cytotoxic
triphenyltin(IV) compound in the present report (3) with an
average ID50 value of around 35 ng/ml is found to be more
cytotoxic for all the cell lines studied than doxorubicin,
cisplatin, 5-fluorouracil and etoposide.
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Introduction
One of the most important goals of pharmacological
research is the search for new molecular structures which
exhibit effective antitumour activities [1–2]. This has driven
inorganic and organometallic chemists to look for new
metal compounds with good activities, preferably against
tumours that are responsible for high cancer mortality.
Organotin(IV) compounds are a widely studied class of
metal-based antitumour drugs and their intensive investiga-
tion has led to the discovery of compounds with excellent
in vitro antitumour activity, but, in many cases, disappoint-
ingly low in vivo potency or high in vivo toxicity [3–5]. It
is well established that organotin(IV) compounds are very
important in cancer chemotherapy because of their apopto-
tic inducing character [6, 7]. The design of improved
organotin(IV) antitumour agents occupies a significant
place in cancer chemotherapy, as revealed from their
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remarkable therapeutic potential reflected in recent research
reports [8–19].
The binding ability of organotin(IV) compounds towards
DNA depends on the coordination number and nature of the
groups bonded to the central tin atom. The phosphate group
of DNA sugar backbones usually acts as an anchoring site
and the nitrogen of DNA base binding is extremely
effective, this often resulting in the stabilization of the tin
center as an octahedral species. Low doses of organotins
can exhibit anti-tumoural activity [20–25] and have
suggested an action mode via a gene-mediated pathway in
the cancer cells, opening a new research sub-area on
organotin(IV) compounds. The chemical and biochemical
aspect of DNA inhibition, including biotechnological
aspects of organotin(IV) cancer chemotherapy, has also
been described [26].
Organotin(IV) halides and their complexes with amines
and other ligands exhibit borderline activities in vivo
against P388 and L1210 leukaemia. The in vivo pre-
screenings against these two cancers used initially by the
National Cancer Institute (NCI), USA, were later replaced
by in vitro pre-screenings against a panel of human tumour
cell lines, viz., MCF-7 and EVSA-T ( mammary cancers),
WIDR (colon cancer), IGROV (ovarian cancer), M19 MEL
(melanoma), A498 (renal cancer) and H226 (non-small-cell
lung cancer) [27].
When organotin(IV) halides are dissolved in water, the
pH of the solution decreases dramatically because they are
converted slowly into organotin(IV) hydroxides and then to
bis(triorganotin)oxides or diorganotin oxides. In contrast,
di- and tri-organotin(IV) carboxylates do not suffer from
this disadvantage and generally remain intact in water for
long periods; i.e. days. Consequently, a large number of
organotin(IV) carboxylates have been investigated for their
antitumour potential. Among organotin(IV) carboxylates,
triorganotin(IV) carboxylates are quite well known as
bactericides and fungicides [28, 29] and subsequently
several such derivatives were found to be potent when
screened for their cytotoxicity [30–32]. Exceptionally high
in vitro antitumour activities were also reported for
triphenyltin(IV) benzoates and salicylates against a human
mammary tumour (MCF-7) and a colon carcinoma (WIDR)
and found to be comparable with that of mitomycin C [33].
Several attempts were also made to synthesize triphenyltin
(IV) carboxylates by modifying the carboxylate moiety
with biologically active carboxylate moieties and also by
incorporating lipophilic/hydrophilic properties in them,
since the lipophilic properties are essential for crossing
the cell membrane and their hydrophilic character for being
accepted by the water-rich cell [27]. The promising
development in the search for antitumour organotin(IV)
compounds has been achieved with some triphenyltin(IV)
carboxylates, such as 3,6-dioxaheptanoate and 3,6,9-
trioxadecanoate [34], 4-carboxybenzo-15-crown-5 and 4-
carboxybenzo-18-crown-6 [34, 35], steroidcarboxylate [36]
and terebate [27, 32, 37] when screened in vitro against
human tumour cell lines, as per the NCI protocol.
In view of the increasing interest in organotin(IV)
carboxylates and prompted by their structural diversity
[38] and broad therapeutic activity [27], organotin(IV)
complexes of Schiff bases derived from amino acids have
also been investigated extensively [39–49]. An overview of
the coordination behaviour of such Schiff bases towards
organotin(IV) is shown in Scheme 1. Some of these
organotin(IV) compounds were screened for antitumour
activity in vivo in Ehrlich ascites carcinoma cells [41] and
cytotoxic activity in vitro against cell lines of human
origin [47, 49]. The in vitro cytotoxicity results demon-
strated that triphenyltin(IV) compounds derived from 2-
{[(2Z)-(3-hydroxy-1-methyl-2-butenylidene)]amino}-,
2-{[(E)-1-(2-hydroxyphenyl)methylidene]amino}- and 2-
{[(E)-1-(2-hydroxyphenyl)ethylidene]amino}-phenylpropi-
onates are more active than CDDP (cisplatin) [49].
Interestingly, all three triphenyltin(IV) compounds show
comparable cytotoxic activity across a panel of cell lines
and this prompted us to investigate related systems by
modifying the amino acetate part of the molecule, which
might improve dissolution properties and thereby influence
cytotoxicity. Within this paper, we present a series of new
organotin(IV) carboxylates involving the 2-{[(2Z)-(3-hy-
droxy-1-methyl-2-butenylidene)]amino}-4-methyl-penta-
noate and 2-{[(E)-1-(2-hydroxyphenyl)-alkylidene]amino}-
4-methyl-pentanoate skeletons (Scheme 2, compounds
1–4), their synthesis, spectroscopic characterization, crystal
structures and preliminary cytotoxic studies.
Experimental
Materials
Ph3SnCl (Fluka AG), Ph2SnCl2, 2′-hydroxyacetophenone
(Aldrich), l-leucine (Himedia), 2-hydroxybenzaldehyde and
acetylacetone (Sisco) were used without further purifica-
tion. The solvents used in the reactions were of AR grade
and were dried using standard procedures.
Physical measurements
Carbon, hydrogen and nitrogen analyses were performed
with a Perkin Elmer 2400 series II instrument. IR spectra in
the range 4,000–400 cm−1 were obtained on a Perkin Elmer
Spectrum BX series FT-IR spectrophotometer with samples
Scheme 1 An overview showing the coordination behaviour of Schiff
bases with amino acids towards the organotin(IV) moiety
b
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investigated as KBr discs. The 1H-, 13C- and 119Sn-NMR
spectra were recorded on a Bruker AMX 400 spectrometer
and measured at 400.13, 100.62 and 149.18 MHz. The 1H,
13C and 119Sn chemical shifts were referred to Me4Si set at
0.00 ppm, CDCl3 set at 77.0 ppm and Me4Sn set at
0.00 ppm, respectively.
X-ray crystallography
Crystals of compounds 1 and 3 suitable for an X-ray crystal-
structure determination were obtained from toluene/hexane
(v/v 1:1) and ethanol, respectively, by slow evaporation of
the solutions of the respective compounds. All measure-
ments were made on a Nonius KappaCCD diffractometer
[50] with graphite-monochromated Mo Kα radiation (λ=
0.71073 Å) and an Oxford Cryosystems Cryostream 700
cooler. Data reduction was performed with HKL Denzo and
Scalepack [51]. The intensities were corrected for Lorentz
and polarization effects, and empirical absorption correc-
tions based on the multi-scan method [52] were applied.
Equivalent reflections, other than Friedel pairs, were
merged. The data collection and refinement parameters are
given in Table 1, and views of the molecules are shown in
Figs. 1 and 2. The structure of 1 was solved by direct
methods using SIR92 [53]. Heavy-atom Patterson methods
[54] were employed for 3, which revealed the position of
the Sn-atom, and the remaining non-hydrogen atoms in 3
were located in a Fourier expansion of the Patterson
solution, which was performed by DIRDIF94 [55].
Both triphenyltin(IV) compounds exist as polymeric
chains with the carboxylate ligands bridging between the
Sn-atoms and in each case the asymmetric unit contains just
one of the chemical repeat units of the polymer. One of the
phenyl ligands in 1 and 3 and the iso-propyl group in 1 are
disordered over two orientations. Two sets of overlapping
positions were defined for the atoms of the disordered
groups and the site occupation factors of the major
conformations of these groups refined to 0.578(9), 0.552(8)
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Scheme 2 Syntheses of potassium salts (L1HK-L3HK) along with the numbering scheme and their triphenyltin(IV) complexes (1–3). The
structure of diphenyltin(IV) complex (4) is included for the convenience of discussion
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and 0.70(1), respectively. Similarity restraints were applied
to the chemically equivalent bond lengths and angles
involving all disordered C-atoms, while neighbouring
atoms within and between each conformation of the
disordered groups were restrained to have similar atomic
displacement parameters.
The imine H-atom in 1 was placed in the position
indicated by a difference electron density map and its
position was allowed to refine together with an isotropic
displacement parameter. All remaining H-atoms were
placed in geometrically calculated positions and refined
by using a riding model where each H-atom was assigned a
fixed isotropic displacement parameter with a value equal
to 1.2Ueq of its parent C-atom (1.5Ueq for the methyl
groups). The refinement of each structure was carried out
on F2 by using full-matrix least-squares procedures, which
minimized the function
P
w F2o  F2c
 2
. Corrections for
secondary extinction were applied. Two reflections in 3,
whose intensities were considered to be extreme outliers,
were omitted from the final refinement. Refinement of the
absolute structure parameter [56] for 1 and 3 yielded the
values of −0.02(2) and −0.05(3), respectively, which
confidently confirm that the refined coordinates represent
the true enantiomorph. All calculations were performed
using the SHELXL97 program [57].
Several crystals of 2 were tried, but all seem to exhibit
diffuse scattering. Although the overall structure could be
discerned and is very similar to that of 3, the R-factors
remained very high, the refinement is unstable because of
pseudosymmetry, and there is some unresolvable disorder at
the chiral centre of the l-leucine ligand. For these reasons, the
details of this structure are not reported here. Visual
inspection of the crystals showed that they tended to grow
in layered blocks. An individual layer could be isolated by
careful cutting, but this did not yield improved data. It is
possible that twinning has occurred, although twin analysis
software did not reveal any twin laws and reconstructed
precession images were also reasonably clean. Data collection
at various temperatures did not improve the results.
Synthesis
Synthesis of the potassium salts
A typical procedure is described below.
Potassium 2-{[(2Z)-(3-hydroxy-1-methyl-2-butenyli-
dene)]amino}-4-methyl-pentanoate (L1HK) was prepared
by slow addition of a methanol solution (2 ml) of KOH
(0.19 g, 3.38 mmol) to l-leucine (0.44 g, 3.35 mmol) in
10 ml methanol with continuous stirring. A methanolic
solution (15 ml) of acetylacetone (0.33 g, 3.29 mmol) was
added drop-wise. A pale yellow colour developed almost
immediately and stirring was continued for 1 h, followed by
5 h refluxing. The volatiles were removed carefully; the
pale yellow mass was stirred with diethylether and filtered.
The residue was dissolved in the minimum amount of
anhydrous methanol and filtered. The filtrate was precipi-
tated with diethylether which afforded the crude product.
Repeated precipitations from a methanol-diethylether mix-
ture yielded pure L1HK, which was then dried in vacuo
(0.68 g, 81% yield). M.p.: 70–72°C. Anal. Calc. for
C11H18NKO3: Theory: C, 52.56; H 7.21; N; 5.57%. Found:
C, 52.50; H, 7.16; N, 5.52%. IR absorptions (cm−1): 1,672
ν(OCO)asym, 1,606 ν(C=N), 1,301 ν(Ph(C-O)).
The other potassium salts (Scheme 2), viz., potassium
2-{[(E)-1-(2-hydroxyphenyl)methylidene]amino}-4-meth-
yl-pentanoate (L2HK) and potassium 2-{[(E)-1-(2-hydrox-
yphenyl)ethylidene]amino}-4-methyl-pentanoate (L3HK)
were prepared analogously by reacting 2-hydroxybenzalde-
hyde and 2′-hydroxyacetophenone, respectively, with po-
tassium l-leucinate. L2HK: Recrystallized from methanol to
give a bright yellow precipitate in 83.7% yield. M.p.: 153–
55°C. Anal. Calc. for C13H16NKO3: Theory: C, 57.11; H,
5.90; N, 5.12%. Found: C, 57.03; H, 5.88; N, 5.10%. IR
absorptions (cm−1): 1,639 ν(OCO)asym, 1,613 ν(C=N),
1,374 ν(Ph(C-O)). L3HK: Recrystallized from methanol to
Table 1 Crystallographic data and structure refinement parameters for
organotin(IV) compounds 1 and 3
1 3
Empirical formula C29H33NO3Sn C32H33NO3Sn
Formula weight 562.18 598.22
Crystal size (mm) 0.20×0.25×0.30 0.10×0.12×0.17
Crystal shape Prism Prism
Temperature (K) 250(1) 160(1)
Crystal system Orthorhombic Monoclinic
Space group P212121 P21
a (Å) 9.2766(1) 9.3293(2)
b (Å) 14.0307(2) 13.6667(3)
c (Å) 21.2691(2) 11.1178(2)
β (°) 90 91.713(1)
V (Å3) 2768.33(6) 1416.89(5)
Z 4 2
Dx (g cm
−3) 1.349 1.402
μ (mm−1) 0.950 0.933
Transmission factors
(min, max)
0.769; 0.834 0.829; 0.914
2θmax (°) 55 55
Reflections measured 74188 32799
Independent reflections; Rint 6331; 0.072 6469; 0.056
Reflections with I>2σ(I) 5409 5819
Number of parameters 401 393
Number of restraints 251 170
R(F) [I>2σ(I)reflns] 0.036 0.046
wR(F2) (all data) 0.084 0.114
GOF(F2) 1.09 1.11
Δρmax, min (e Å
−3) 0.98; −0.40 1.43; −0.75
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give a yellow precipitate in 78.7% yield. M.p.: 145–47°C
(decomp.). Anal. Calc. for C14H18NKO3: Theory: C, 58.51;
H, 6.31; N, 4.87%. Found: C, 58.40; H, 6.20; N, 5.04%. No
meaningful IR spectrum could be recorded owing to fast
decomposition of the sample.
Synthesis of the organotin(IV) complexes
Synthesis of [Ph3SnL
1H]n (1)
Ph3SnCl (0.55g, 1.43 mmol) in anhydrous methanol (ca.
10 ml) was added drop-wise to a stirred anhydrous
methanol solution (ca. 20 ml) containing L1HK (0.36g,
1.43 mmol). The solution was refluxed for 5 h at ambient
temperature and the volatiles were removed in vacuo. The
residue was washed thoroughly with hexane, filtered and dried
in vacuo. The residue was extracted into anhydrous benzene
and filtered. The benzene solution was concentrated to a
minimum and precipitated with hexane. The precipitate was
washed several times with hexane, dried in vacuo and
recrystallized from toluene-hexane mixture (1:1 v/v) to yield
colourless crystals of 1 in 83.5% (0.66g) yield. M.p.: 135–
137°C. Anal. Calc. for C29H33NO3Sn: Theory: C, 61.95;
H, 5.92; N, 2.49%. Found: C, 61.90; H, 5.85; N, 2.40%.
IR absorptions (cm−1): 1,646 ν(OCO)asym, 1,600 ν(C=N),
1,261 ν(Ph(CO)). 1H-NMR (CDCl3): Ligand skeleton:
10.92 (brs, 1H, OH), 4.97 (s, 1H, H-4), 4.18 (d (7.7 Hz);
3J(119/117Sn-1H=22 Hz)), 1H, H-2), 2.01 (s, 2H, H-6), 1.74
(s, 6H, H-3′ and H-5′), 1.59 (s, 1H, H-7), 0.91 and 0.85 (d
(7 Hz), 6H, H-8a and H-8b); Sn-Ph skeleton: 7.78 (m, 6H,
H-2*), 7.45 (m, 9H, H-3* and H-4*), ppm. 13C-NMR
(CDCl3): Ligand skeleton: 195.4 (C-1), 177.9 (C-5), 162.3
(C-3), 96.3 (C-4), 55.1 (C-2), 41.9 (C-6), 28.9 (C-7), 24.8
and 18.9 (C-3′ and C-5′), 22.9 and 21.8 (C-8a and C-8b);
Sn-Ph skeleton (nJ(13C-119/117Sn, Hz)): 137.9 (662/634)
(C-1*), 136.9 (48) (C-2*), 130.3 (14) (C-4*), 129.0 (64)
(C-3*), ppm. 119Sn-NMR (CDCl3): −103.7 ppm.
Synthesis of [Ph3SnL
2H]n (2)
An identical method to that used for the preparation of 1
was followed using Ph3SnCl and L
2HK. Yellow crystals of
Fig. 1 Three repeats of the
crystallographically and chemi-
cally unique unit in the poly-
meric [Ph3SnL
1H]n chain
structure of 1 (50% probability
ellipsoids). The H-atoms and
one of the disordered conforma-
tions have been omitted for
clarity
Fig. 2 Three repeats of the
crystallographically and chemi-
cally unique unit in the poly-
meric [Ph3SnL
3H]n chain
structure of 3 (50% probability
ellipsoids). The H-atoms and
one of the disordered conforma-
tions have been omitted for
clarity
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compound 2 were obtained from ethanol in 79% yield. M.
p.: 153–55°C. Anal. Calc. for C31H31NO3Sn: Theory: C,
63.73; H, 5.35; N, 2.40%. Found: C, 63.65; H, 5.30; N,
2.45%. IR absorptions (cm−1): 1,646 ν(OCO)asym, 1,546
ν(C=N), 1,288 ν(Ph(CO)). 1H-NMR (CDCl3): Ligand
skeleton: 13.3 (brs, 1H, OH), 8.32 (s, 1H, H-3′), 7.31 (t,
1H, H-7), 7.20 (d, 1H, H-9), 6.97 (d, 1H, H-6), 6.86 (t, 1H,
H-8), 4.16 (d (3.3 Hz); 3J(119/117Sn-1H=14 Hz)), 1H, H-2),
1.88 (s, 2H, H-10), 1.58 (s, 1H, H-11), 0.90 and 0.86 (d
(7 Hz), 6H, H-12a and H-12b); Sn-Ph skeleton: 7.71 (m,
6H, H-2*), 7.45 (m, 9H, H-3* and H-4*), ppm. 13C-NMR
(CDCl3): Ligand skeleton: 177.6 (C-1), 165.8 (C-5), 161.4
(C-3), 132.5 (C-7), 131.6 (C-9), 118.8 (C-4), 118.5 (C-8),
117.2 (C-6), 69.7 (C-2), 42.9 (C-10), 24.7 (C-11), 23.1 and
21.6 (C-12a and C-12b); Sn-Ph skeleton (nJ(13C-119/117Sn,
Hz)): 137.9 (654/627) (C-1*), 136.9 (48) (C-2*), 130.3 (16)
(C-4*), 129.0 (63) (C-3*), ppm. 119Sn-NMR (CDCl3):
−100.2 ppm.
Synthesis of [Ph3SnL
3]n (3)
A mixture of Ph3SnCl (0.80g, 2.07 mmol) and L
3HK
(0.60g, 2.08 mmol) was refluxed in benzene (35 ml) for
6 h. The bright yellow solution was filtered and the filtrate
was evaporated to a minimum and precipitated with hexane
to give the crude product. The precipitate was filtered, dried
in vacuo and upon recrystallization from ethanol furnished
light fluorescent yellow crystals of 3 in 86% (1.07 g) yield.
M.p.: 158-60°C. Anal. Calc. for C32H33NO3Sn: Theory: C,
64.24; H, 5.56; N, 2.34%. Found: C, 63.89; H, 5.46; N,
2.21%. IR absorptions (cm-1): 1,653 ν(OCO)asym, 1,613
ν(C=N), 1,261 ν(Ph(CO)). 1H-NMR (CDCl3): Ligand
skeleton: 16.1 (brs, 1H, OH), 7.41 (m (overlapped with
Sn-Ph H-3* and H-4*), 1H, H-9), 7.31 (t, 1H, H-7), 6.97
(d, 1H, H-6), 6.78 (t, 1H, H-8), 4.53 (d (3.3 Hz);
3J(119/117Sn-1H=14 Hz)), 1H, H-2), 2.64 (s, 2H, H-10),
2.22 (s, 1H, H-3′), 1.93 (s, 1H, H-11), 0.92 and 0.85
(d (7 Hz), 6H, H-12a and H-12b); Sn-Ph skeleton: 7.65 (m,
6H, H-2*), 7.41 (m, 9H, H-3* and H-4*), ppm. 13C-NMR
(CDCl3): Ligand skeleton: 177.5 (C-1), 172.3 (C-5), 163.8
(C-3), 132.6 (C-7), 128.3 (C-9), 118.9 (C-4), 118.8 (C-8),
117.1 (C-6), 60.8 (C-2), 43.1 (C-10), 25.0 (C-11), 23.0 and
21.9 (C-12a and C-12b), 14.9 (C-3′); Sn-Ph skeleton
(nJ(13C-119/117Sn, Hz)): 137.9 (654/627) (C-1*), 136.7
(50) (C-2*), 129.9 (16) (C-4*), 128.8 (64) (C-3*), ppm.
119Sn-NMR (CDCl3): −83.1 ppm.
Synthesis of [Ph2SnL
2H]n (4)
Ph2SnCl2 (0.50 g, 1.42 mmol) in hot anhydrous benzene
(45 ml) was added drop-wise to L2HK (0.39 g, 1.42 mmol)
suspended in anhydrous benzene (30 ml) with continuous
stirring. The reaction mixture was refluxed for 1 h, then
triethylamine (0.15 ml, 1.42 mmol) was added and
refluxing was continued for an additional 5 h. The reaction
mixture was cooled to room temperature and filtered to
remove Et3N.HCl. The filtrate was collected; volatiles were
removed in vacuo. The dried residue was washed thor-
oughly with hexane and then extracted into warm benzene
(25 ml) and filtered. The filtrate was concentrated,
precipitated with hexane, filtered and the light yellow
residue obtained was dried in vacuo. The crude product was
then re-crystallized from ethanol which afforded a lemon
yellow microcrystalline product of 4 in 76.7% (0.69 g)
yield. M.p.: 191–193°C (207–208°C [58]). Anal. Calc. for
C25H25NO3Sn: Theory: C, 59.32; H, 4.98; N, 2.77. Found:
C, 59.29; H, 4.90; N, 2.84 %. IR absorptions (cm−1): 1,686
ν(OCO)asym, 1,619 ν(C=N), 1,321 ν(Ph(CO)).
1H-NMR
(CDCl3): Ligand skeleton: 8.22 (s, (
3J(119/117Sn-1H=
57 Hz)), 1H, H-3′), 7.55 (t, 1H, H-7), 7.19 (d, 1H, H-9),
7.15 (d, 1H, H-6), 6.81 (t, 1H, H-8), 4.17 (d (3.0 Hz); (3J
(119/117Sn-1H=14 Hz)), 1H, H-2), 1.81 and 1.52 (m, 2H, H-
10), 1.63 (m, 1H, H-11), 0.90 and 0.81 (d (7 Hz), 6H,
H-12a and H-12b); Sn-Ph skeleton: 7.98 and 7.82 (m, 4H,
H-2*), 7.47 and 7.36 (m, 6H, H-3* and H-4*), ppm. 13C-
NMR (CDCl3): Ligand skeleton: 173.7 (C-1), 171.6 (C-5),
169.2 (C-3), 138.0 (C-7), , 135.5 (C-9), 122.8 (C-8), 117.8
(C-6), 117.1 (C-4), 67.6 (C-2), 44.7 (C-10), 23.7 (C-11),
22.7 and 21.8 (C-12a and C-12b); Sn-Ph skeleton (nJ
(13C-119/117Sn, Hz)): 137.5 (994) and 137.4 (962) (C-1*),
136.5 (57) and 136.2 (57) (C-2*), 130.7 (98) and 130.6 (78)
(C-4*), 128.8 (17) and 128.7 (17) (C-3*), ppm. 119Sn-NMR
(CDCl3): −340.5 ppm.
Experimental protocol and cytotoxicity tests
The experiment was started on day 0. On day 0, 10,000
cells per well were seeded into 96-wells flat-bottomed
micro-titer plates (falcon 3072, DB). The plates were pre-
incubated overnight at 37°C, 5% CO2 to allow the cells to
adhere to the bottom. On day 1, a three-fold dilution
sequence of ten steps was made in full medium, starting
with the 250,000 ng/ml stock solution. Every dilution was
used in quadruplicate by adding 200 μl to a column of four
wells. This procedure results in the highest concentration of
625,000 ng/ml being present in column 12. Column 2 was
used for the blank. After incubation of 3 days, the plates
were washed with PBS twice. Fluorescein diacetate (FDA)
stock solution was diluted to 2 μg/ml with PBS and 200 μl
of this solution was added to each of the control,
experimental and blank wells. The plates were incubated
for 30 min at 37°C and the fluorescence generated from
each well was measured at an excitation wavelength of
485 nm and an emission wavelength of 535 nm using an
automated microplate reader (Labsystems Multiskan MS).
The data were used for construction of concentration-
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response curves and determination of the ID50 values by
use of Deltasoft 3 software.
The variability of the in vitro cytotocicity test depends
on the cell lines used and the serum applied. With the same
batch of cell lines and the same batch of serum the inter-
experimental CV (coefficient of variation) is 1–11%
depending on the cell line and the intra-experimental CV
is 2–4%. These values may be higher with other batches of
cell lines and/or serum.
Results and discussion
Synthesis and spectroscopy
Potassium salts L1HK- L3HK were prepared by reacting
acetylacetone, 2-hydroxybenzaldehyde or 2′-hydroxyaceto-
phenone with potassium l-leucinate in methanol. Triphe-
nyltin(IV) compounds viz., [Ph3SnL
1H]n (1), [Ph3SnL
2H]n
(2) and [Ph3SnL
3H]n (3) could easily be prepared by
reacting potassium salts with Ph3SnCl either in refluxing
methanol or benzene in greater than 76% yields. On the
other hand, [Ph2SnL
2H]n (4) was prepared by reacting
the appropriate potassium salt with Ph2SnCl2 in benzene in
the presence of Et3N as a proton abstractor, a method
similar to that reported earlier [59]. The synthesis of these
compounds is shown in Scheme 2. The compounds are
shiny colourless to yellow solids. They are stable in air and
soluble in all common organic solvents.
The IR spectra displayed a strong sharp band at around
1,650 cm−1 for triphenyltin(IV) complexes (1–3) and at
around 1,685 cm−1 for diphenyltin(IV) complex (4) which
has been assigned to the carboxylate antisymmetric
[νasym(OCO)] stretching vibration, in accord with our
earlier reports [39, 42, 43, 47, 49]. The assignment of the
symmetric [νsym(OCO)] stretching vibration band could
not be made owing to the complex pattern of the spectra.
The 1H- and 13C- NMR signals were assigned by the use
of homonuclear correlated spectroscopy (COSY), hetero-
nuclear single-quantum correlation (HSQC), heteronuclear
multiple-bond connectivities (HMBC) and distortionless
enhancement by polarization transfer (DEPT) experi-
ments. The 1H and 13C chemical shift assignment (see
Experimental) of the phenyltin moiety is straightforward
from the multiplicity patterns, resonance intensities and
also by comparing their nJ(13C-119/117Sn) values. The 1H-
NMR integration values were completely consistent with
the formulation of the products. The 13C-NMR spectra of
the ligand and Sn-Ph skeletons displayed the expected
carbon signals in triphenyltin(IV) complexes 1–3. The
diphenyltin(IV) complex (4) deserves specific mention.
The spin-spin coupling of 57 Hz between the azomethine
proton and the tin nucleus, 3J(119/117SnN=C1H) has been
detected. Such coupling has previously been reported for
the complexes where tin nuclei are located in a trans-
position to the azomethine proton [60], confirming the
presence of nitrogen-tin coordination. In addition, com-
plex 4 (Ph2Sn(2-OC6H4C(H)=NCHCH2CH(CH3)2COO)
displayed two sets of 1H and 13C NMR signals from the
Sn-Ph groups (see experimental) since the italicised proton
in the complex is enantiotropic and causes the phenyl
groups bound to the tin, and the iBu group to be
diastereotopic [61], and thereby the two phenyl groups
(Sn-Ph2) experience different environments on the NMR
time scale. These observations were noted earlier for
diorganotin(IV) complexes of 2-{[(E)-1-(2-oxyphenyl)
alkylidene]amino}phenylpropionate [49]. The triphenyl-
tin(IV) complexes (1–3) in CDCl3 exhibit a single sharp
119Sn resonance in the range −83 to −103 ppm, suggesting
that the Sn-atoms in the complexes have the same four-
coordinate environment [42, 47, 49, 62, 63]. This is also
reflected in 1J(13C-119/117Sn) coupling constants (see
experimental) and the values are unambiguously characteris-
tic for four-coordinate tin atoms [63]. These results demon-
strate that the polymeric structure with five-coordinate tin
atoms found in the solid state is lost upon dissolution (see
below for the crystal structure discussion). On the other
hand, the X-ray crystal structure of complex 4 demon-
strated a pseudo-trigonal bipyramid geometry around the
tin atom [58]. The chemical shift data for this complex in
CDCl3 displayed a
119Sn chemical shift at -340 ppm,
which closely matches the shifts reported for diphenyltin
(IV) amino acetate [39, 41], which has five-coordinate Sn-
atoms in solution. This shift testifies that the solid state
structure of 4, revealed in the crystal structure, is retained
in solution.
Crystal structures
The crystal structures of compounds 1 and 3 reveal that the
Sn-coordination complex in each case has the basic type X
polymeric chain structural motif described in Scheme 1. A
preliminary investigation of the crystal structure of 2
revealed the same motif, but this structure is not described
in any further detail here (see the “Experimental” for
details). Views of the molecular structures of complexes 1
and 3 are shown in Figs. 1 and 2 (refer to Scheme 2 for line
diagrams), while selected geometric parameters are collect-
ed in Table 2.
The following specific details are given for the structure
of 1, but the comments apply equally well to the structures
of 2 and 3. It is apparent that varying the organic moiety in
the Schiff base ligands has an insignificant influence on the
overall structure and the coordination geometry of the Sn-
atoms. Complex 1 has a polymeric chain structure in which
a single carboxylate ligand bridges adjacent Sn-centres via
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its carboxylate and oxide O-atoms. The asymmetric unit
contains one of the chemical repeat units of the polymeric
Sn-compound. Compounds 1 and 3 in the crystal are
enantiomerically pure and the absolute configuration of the
molecules has been determined independently by the
diffraction experiments. The stereogenic centre at C(2) of
the molecules 1 and 3 has the S-configuration expected of
l-leucine.
The primary coordination sphere of the Sn-atom is trigonal
bipyramidal with the phenyl ligands in the equatorial plane and
the axial positions occupied by one O-atom from the
carboxylate group of one carboxylate ligand and the oxide
O-atom of the next carboxylate ligand in the chain. This yields
a trans-R3SnO2 geometry. The second O-atom of the
carboxylate group is not involved in the primary coordination
sphere of the Sn-atom, but lies 3.386(3) Å (3.537(5) Å in 3)
from the Sn-atom. Polymeric chain structures involving
triphenyltin(IV) and the Schiff bases of amino acids with a
similar mode of coordination and geometry about the
Sn-atom have been observed in triphenyltin 2-{[(E)-1-(2-
hydroxyphenyl)methylidene]amino}acetate [42], 2-{[(2Z)-(3-
hydroxy-1-methyl-2-butenylidene)]amino}phenylpropionate
[49], 2-{[(E)-1-(2-hydroxyphenyl) methylidene]amino}phe-
nylpropionate [49] and 2-{[(E)-1-(2-hydroxyphenyl)ethyl-
idene]amino}- phenylpropionate [49]. Among all of these
structures, the greatest variation in the coordination geometry
is in the Sn-O(oxide) bond length, which ranges from 2.242
(2) Å in 3 to 2.539(2) Å in 2-{[(E)-1-(2-hydroxyphenyl)
methylidene]amino}phenylpropionate [49]. The formal hy-
droxy group in the carboxylate ligand of 1 and 3 has lost its
H-atom, so is negatively charged. Instead the imine N-atom is
protonated, thus leading to a zwitterionic ligand. This N+–H
group forms a strong intramolecular hydrogen bond with the
oxide O atom (Table 3). One of the phenyl ligands and the
iso-propyl group in 1 are disordered over two orientations
while one of the phenyl ligands is disordered over two almost
equally occupied orientations in 3.
The polymeric structures of the triphenyltin(IV) com-
plexes 1–3 is not repeated in the crystal structure of
diphenyltin(IV) complex 4, which was described by Wang
et al. [58]. In 4, a mononuclear discrete molecule, the
arrangement of the donor set about the Sn-atom is distorted
trigonal bipyramidal with one carboxylate and the oxide
oxygen atoms from the tridentate carboxylate ligand
occupying the axial positions, while the imine nitrogen
atom from the carboxylate ligand and two phenyl groups
are in equatorial positions (refer to Scheme 2).
Cytotoxicity studies
The in vitro cytotoxicity test of organotin(IV) compounds
1-4 was performed using the SRB test for the estimation of
cell viability. The cell lines WIDR, M19 MEL, A498,
IGROV and H226 belong to the currently used anticancer
screening panel of the NCI, USA [64]. The MCF7 cell line
is estrogen receptor (ER)+/ progesterone receptor (PgR)+
and the cell line EVSA-T is (ER)−/(Pgr)−. Prior to the
experiments, a mycoplasma test was carried out on all cell
lines and found to be negative. All cell lines were
maintained in a continuous logarithmic culture in RPMI
1640 medium with Hepes and phenol red. The medium was
supplemented with 10% FCS, penicillin 100 μg/ml and
streptomycin 100 μg/ml. The cells were mildly trypsinized
for passage and for use in the experiments. RPMI and FCS
were obtained from Life technologies (Paisley, Scotland).
SRB, DMSO, Penicillin and streptomycin were obtained
from Sigma (St. Louis MO, USA), TCA and acetic acid
from Baker BV (Deventer, NL) and PBS from NPBI BV
Table 2 Selected bond lengths (Å) and angles (°) for compounds (1
and 3)
1 3
Sn(1)-O(1) 2.151(2) Sn-O(1) 2.197(4)
Sn(1)-O(2) 3.386(3) Sn-O(2) 3.537(5)
Sn(1)-C(11) 2.136(4) Sn-C(14) 2.124(5)
Sn(1)-C(17) 2.132(4) Sn-C(20) 2.118(5)
Sn(1)-C(23a) 2.132(4) Sn-C(26a) 2.135(5)
Sn(1)-C(23b) 2.129(5) Sn-C(26b) 2.143(5)
Sn(1)-O(3′) 2.352(2) Sn-O(3′) 2.242(4)
O(1)-Sn(1)-C(11) 97.3(1) O(1)-Sn-C(14) 94.4(2)
O(1)-Sn(1)-C(17) 95.6(1) O(1)-Sn-C(20) 92.6(2)
O(1)-Sn(1)-C(23a) 85.3(4) O(1)-Sn-C(26a) 90.5(6)
O(1)-Sn(1)-C(23b) 90.7(6) O(1)-Sn-C(26b) 80.4(4)
C(11)-Sn(1)-C(17) 122.2(1) C(14)-Sn-C(20) 120.2(2)
C(17)-Sn(1)-C(23a) 119.8(4) C(20)-Sn-C(26a) 109.7(5)
C(17)-Sn(1)-C(23b) 111.8(6) C(20)-Sn-C(26b) 120.2(5)
C(23a)-Sn(1)-C(11) 117.2(5) C(26a)-Sn-C(14) 129.5(4)
C(23b)-Sn(1)-C(11) 124.0(7) C(26b)-Sn-C(14) 119.5(4)
O(3′)-Sn(1)-C(11) 87.5(1) O(3′)-Sn-C(14) 89.1(2)
O(3′)-Sn(1)-C(17) 87.5(1) O(3′)-Sn-C(20) 93.0(2)
O(3′)-Sn(1)-C(23a) 86.4(4) O(3′)-Sn-C(26a) 80.7(6)
O(3′)-Sn(1)-C(23b) 81.0(6) O(3′)-Sn-C(26b) 90.5(4)
O(1)-Sn(1)-O(3′) 171.7(1) O(1)-Sn-O(3′) 170.8(1)
C(1)-O(1)-Sn(1) 125.5(2) C(1)-O(1)-Sn 130.9(3)
C(9′)-O(3′)-Sn(1) 134.9(2) C(13′)-O(3′)-Sn 130.2(3)
Primed atoms refer to atoms from the next symmetrically-related
ligand in the polymeric chain (symmetry code for 1: 1−x,  12þ y,1
2 z; for 3: 2−x, 12þ y, 1−z)
Table 3 Hydrogen bonding geometry (Å, °) for compounds 1 and 3
D-H···A D-H H···A D···A D-H···A
1 N(1)-H(1)···O(3) 0.86(4) 2.00(3) 2.668(4) 134(3)
3 N(1)-H(1)···O(3) 0.88 1.80 2.546(5) 141
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(Emmer-Compascuum, NL). The test compounds 1–4 and
reference compounds were dissolved to a concentration of
250,000 ng/ml in full medium, by 20 fold dilution of a
stock solution which contained 1 mg of compounds 1–4/
200 μl. All the four compounds were dissolved in DMSO.
Cytotoxicity was estimated by the microculture sulforhod-
amine B (SRB) test [65].
The results of the in vitro cytotoxicity tests performed
with triphenyltin(IV) compounds, (1–3) and diphenyltin
(IV) compound (4) are summarized in Table 4 and the
screening results are compared with the results from other
related triphenyltin(IV)- and diorganotin(IV)- compounds
with respect to the standard drugs that are in current clinical
use as antitumour agents. Recently, we have reported in
vitro cytotoxic results on triphenyltin(IV) compounds 5–7
where the ligand is a Schiff base derived from phenylala-
nine [49]. There are also reports on di-n-butyltin(IV) and
diphenyltin(IV) compounds with Schiff bases derived from
glycine, β-alanine, and l-leucine and these were also
investigated for in vitro cytotoxic potential (see Table 4
for details) [66]. The di-n-butyltin(IV) compounds of cognate
systems were also investigated for antitumour activity
against the NCI panel of 60 cell lines [67]. The results
indicated that three of the di-n-butyltin(IV) compounds,
viz., nBu2Sn(2-OC6H4C(H)=NCH2COO),
nBu2Sn(2-
OC6H4C(CH3)=NCH2COO) and
nBu2Sn(2-OC6H4C(H)=N
CHCH(CH3)2COO) exhibited very high cytotoxic effects on
the NCI-522 (non-small cell lung cancer) cell line. The
fourth compound, nBu2Sn(2-OC10H6C(H)=NCH2COO)
exhibited highest cytotoxic activity on the cell line RXF-
Table 4 In vitro ID50 values (ng/ml) of test compounds 1–4 and some reported organotin(IV) compounds compared with some standard drugs
used in cell viability tests against seven human tumour cell lines
Test compounda Cell lines
A498 EVSA-T H226 IGROV M19 MEL MCF-7 WIDR
[Ph3SnL
1H]n (1) 96 35 56 90 42 36 33
[Ph3SnL
2H]n (2) 104 49 111 99 75 76 42
[Ph3SnL
3H]n (3) 39 31 38 46 36 34 31
Ph2SnL
2 (4) 987 278 849 199 409 452 405
[Ph3SnL
4H]n.nCCl4 (5)
b [49] 105 81 105 101 102 111 106
[Ph3SnL
5H]n (6)
b [49] 120 100 115 105 130 115 110
[Ph3SnL
6H]n (7)
b [49] 113 96 108 106 112 110 109
{[nBu2Sn(2-OHC6H4C(CH3)=N(CH2)2COO)]2O}2 [47] 376 34 237 174 225 147 895
DOX 90 8 199 60 16 10 11
CDDP 2253 422 3269 169 558 699 967
5-FU 143 475 340 297 442 750 225
MTX 37 5 2287 7 23 18 <3.2
ETO 1314 317 3934 580 505 2594 150
TAX <3.2 <3.2 <3.2 <3.2 <3.2 <3.2 <3.2
nBu2Sn(2-OC10H6C(H)=NCH2COO) [66] 170 35 190 75 90 75 480
nBu2Sn(2-OC10H6C(H)=N(CH2)2COO) [66] 62 17 160 27 71 20 114
nBu2Sn(2-OC(CH3)C(H)C(CH3)=NCHCH2CH(CH3)2COO [66] 130 120 200 130 70 60 420
Ph2Sn(2-OC10H6C(H)=NCH2COO) [66] 230 70 350 120 530 170 490
Ph2Sn(2-OC10H6C(H)=N(CH2)2COO) [66] 690 150 1100 480 620 600 1750
DOX 55 13 180 150 21 25 18
CDDP 1200 920 3160 230 780 1400 1550
5-FU 340 720 5300 850 310 350 440
MTX 16 26 70 20 18 15 7
Carboplatin 18,000 4,500 25,000 2,400 5,500 10,500 3,500
Ph3SnR1
c [27] 42 <3 39 19 42 17 17
Ph3SnR2
c [27] 65 <3 61 18 51 16 19
Ph3SnR3
c [27] <2 <2 <2 <2 <2 2.9 <2
CDDP 2,253 422 3,269 169 558 699 967
DOX 90 8 199 60 16 10 11
DOX doxorubicin, CDDP cisplatin, 5-FU 5-fluorouracil, MTX methotrexate, ETO etoposide, TAX paclitaxel
a Standard drug reference values are cited immediately after the test compounds under identical conditions
b Reported triphenyltin(IV) compounds (5–7) have been included for comparison; 49: LH is a carboxylate residue where L4H, 2-{[(2Z)-(3-
hydroxy-1-methyl-2-butenylidene)]amino}phenylpropionate; L5 H, 2-{[(E)-1-(2-hydroxyphenyl)methylidene]amino}phenylpropionate; L6 H, 2-
{[(E)-1-(2-hydroxyphenyl)ethylidene]amino}- phenylpropionate
c Reported triphenyltin(IV) compounds, R is a carboxylate residue where R1=-terebate, R2=-steroidcarboxylate, R3=-benzocrowncarboxylate
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631L (renal cancer). In general, a low to moderate cellular
response was observed for all the di-n-butyltin(IV) com-
pounds, with at least one cell line in each subpanel of cells
exhibiting a very low growth inhibition response. The results
also indicated that the compounds did not exhibit
any significant subpanel activity and suggested that the
di-n-butyltin(IV) compounds were not active in all the
cell lines contained in any subpanel. The di-n-butyltin(IV)
compound of composition {[nBu2Sn(2-OHC6H4C(CH3)=N
(CH2)2COO)]2O}2 (Table 4) also exhibited good activity
especially when compared with CCDP [47]. Another
interesting mixed organotin(IV) binuclear compound Ph3Sn
(HL).Ph2SnL (L=2-O-3,5-Br2C6H2C(H)=NCHCH
(CH3)2COO) also displayed good in vitro cytotoxicity against
three human tumour cell lines, i.e. HeLa (cervix tumour cell),
CoLo 205 (colon carcinoma cell) and MCF-7 (mammary
tumour cell) when compared with CCDP [68, 69].
The triphenyltin(IV) compounds of the present investi-
gation (1-3, Table 4) showed ID50 values in the range 33–
96, 42–104 and 31–38 ng/ml, respectively, whereas
diphenyltin(IV) compound 4 produced an ID50 value in
the range 199–987 ng/ml, across seven human tumour cell
lines. Triphenyltin(IV) compound 3 is the most promising
candidate in this study and the most cytotoxic organotin
(IV) complex so far with a Schiff base bearing amino
acetate skeleton. Compound 3 is around 25 fold more
active in magnitude in terms of the ID50 value at least
against the A498 and H226 cell lines and is found to be
almost as cytotoxic as MTX and found to be much better
particularly for the H226 cell line. Under identical
conditions, compound 3 is far superior to CCDP across a
panel of cell lines and the activity is more pronounced for
the A498 (57 fold) and H226 (86 fold) cell lines. The
increase in the cytotoxicity of triphenyltin(IV) compounds
1–3 across the cell lines is likely to be because of the non-
involvement of the nitrogen atom in the complexation with
the tin atom (see Scheme 2 and Fig. 2), which allows easy
dissociation of the complex so that it can subsequently bind
to DNA. This corroborates the fact that diorganotin(IV)
complexes show lower activity when the nitrogen atom
coordinates to the tin atom [67]. A typical mode of bonding
of diorganotin(IV) complexes is shown in Scheme 2
taking complex 4 as an example. However, the variations
in in vitro cytotoxicity of the triphenyltin(IV) complexes
may be due to different kinetic and mechanistic behaviour
[49]. Conversely, the possibility of organotin compounds
interacting with DNA at the level of the phosphate
groups cannot be completely ruled out [70]. In conclusion,
the present study describes new structures with improved
in vitro anti-tumour activity, which is of added value in
determining the structure activity relationship in the area
of organotin(IV) chemistry with possible future clinical
application.
Conclusions and outlook
The manuscript reports the preparation and crystal struc-
tures of some novel triphenyltin(IV) complexes which may
find applications in cancer chemotherapy. The most
promising triphenyltin(IV) compound 3 shows the highest
cytotoxicity so far among the organotin(IV) compounds
containing Schiff base amino acetate systems when tested
in vitro across seven human tumour cell lines, indicating its
high potential as an anti-cancer drug. It is intended to
employ these compounds for testing in animal models and
additionally to search for differently substituted Schiff base
amino acetate skeletons in order to improve the solubility.
Further work in this area is underway.
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Supplementary Material
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